• Indacaterol + glycopyrronium is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
• It is intended for use in patients who are not adequately controlled with a single bronchodilator or whose disease severity requires dual bronchodilation.

Chronic Obstructive Pulmonary Disease (COPD)

Bronchitis

Emphysema

• The recommended dosage of indacaterol + glycopyrronium may vary depending on the individual patient's needs and the specific product formulation. It is important to follow the instructions provided by the healthcare provider or refer to the product label for precise dosing information.
• The medication is usually administered via inhalation using an appropriate inhaler device. The healthcare provider will provide guidance on the proper inhalation technique.
• For oral inhalation only. Do not swallow indacaterol + glycopyrronium capsules. Only use indacaterol + glycopyrronium capsules with the inhaler device. 
• Maintenance treatment of COPD: The inhalation of the powder contents of prolong QTc interval may potentiate effect on cardiovascular system. Use one indacaterol + glycopyrronium capsule twice-daily.

The following side effects have been reported with indacaterol + glycopyrronium:

• Respiratory tract infections
• Nasopharyngitis (common cold)
• Headache
• Cough
• Diarrhea
• Sinusitis
• Back pain
• Nausea

RTI (Respiratory Tract Infection)

Nasopharyngitis

Headache

Sinusitis

• Do not initiate  in acutely deteriorating COPD  or to  treat acute symptoms. 
• Do not  use in combination with an  additional medicine  containing LABA  because of risk of overdose.
• If  paradoxical bronchospasm  occurs, discontinue indacaterol + glycopyrronium immediately and  institute alternative therapy. 
• Use  with  caution in  patients with cardiovascular or  convulsive disorders,  thyrotoxicosis, sensitivity to sympathomimetic drugs,  diabetes mellitus,  and ketoacidosis. 
• Worsening of narrow-angle glaucoma or urinary retention may occur. Use  with caution in  patients with  narrow-angle glaucoma, prostatic hyperplasia, or  bladder-neck  obstruction and  instruct patients to  contact a physician  immediately if symptoms occur.
• Be alert to hypokalemia and hyperglycemia.
• Respiratory-related effects: Indacaterol + glycopyrronium should be used with caution in patients with a history of asthma or other respiratory conditions, as it may cause paradoxical bronchospasm. Immediate medical attention should be sought if bronchospasm occurs.
• Cardiovascular effects: Patients with a history of cardiovascular disorders should be closely monitored while using this medication, as beta2-adrenergic agonists may have potential cardiovascular effects.
• Hypersensitivity reactions: If signs of hypersensitivity (e.g., rash, itching, swelling) occur, treatment should be discontinued.
• Use in specific populations: The safety and efficacy of indacaterol + glycopyrronium in pediatric patients, pregnant women, and breastfeeding mothers have not been established. Consult a healthcare professional for guidance in these situations.